ADV Trademark

Trademark Overview


On Wednesday, April 27, 2022, a trademark application was filed for ADV with the United States Patent and Trademark Office. The USPTO has given the ADV trademark a serial number of 97383925. The federal status of this trademark filing is ABANDONED - EXPRESS as of Tuesday, May 2, 2023. This trademark is owned by Mercury Pharma Group Limited. The ADV trademark is filed in the Pharmaceutical Products category with the following description:

A full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, acute enterocolitis, duodenal ulcer, and irritable bowel syndrome being irritable colon, spastic colon, mucous colitis; anti-inflammatory medicines, and immunosuppressive agents, namely, corticosteroids; pharmaceutical preparations for the treatment of cancers and abnormal cells; all of the foregoing excluding pharmaceutical preparations acting on the peripheral or central nervous system, surgical kits comprised of medical and surgical apparatus a...
adv

General Information


Serial Number97383925
Word MarkADV
Filing DateWednesday, April 27, 2022
Status601 - ABANDONED - EXPRESS
Status DateTuesday, May 2, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesA full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, acute enterocolitis, duodenal ulcer, and irritable bowel syndrome being irritable colon, spastic colon, mucous colitis; anti-inflammatory medicines, and immunosuppressive agents, namely, corticosteroids; pharmaceutical preparations for the treatment of cancers and abnormal cells; all of the foregoing excluding pharmaceutical preparations acting on the peripheral or central nervous system, surgical kits comprised of medical and surgical apparatus and instruments, and surgical implants comprised of human and animal tissue; all of the foregoing excluding anti-infective pharmaceutical preparations

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 3, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMercury Pharma Group Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLondon EC4N7BL
GB

Trademark Events


Event DateEvent Description
Tuesday, May 2, 2023ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT
Tuesday, May 2, 2023ABANDONMENT - EXPRESS MAILED
Monday, May 1, 2023TEAS EXPRESS ABANDONMENT RECEIVED
Thursday, April 27, 2023LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
Friday, March 24, 2023LETTER OF PROTEST EVIDENCE FORWARDED
Thursday, February 2, 2023TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, January 24, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, January 24, 2023LETTER OF SUSPENSION E-MAILED
Tuesday, January 24, 2023SUSPENSION LETTER WRITTEN
Tuesday, January 24, 2023EXAMINER'S AMENDMENT ENTERED
Tuesday, January 24, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, January 24, 2023EXAMINERS AMENDMENT E-MAILED
Tuesday, January 24, 2023EXAMINERS AMENDMENT -WRITTEN
Wednesday, January 18, 2023ASSIGNED TO EXAMINER
Tuesday, May 3, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, April 30, 2022NEW APPLICATION ENTERED